{
  "company": {
    "name": "Callio Therapeutics",
    "website": "https://calliotx.com/",
    "record": "https://startuphistory.org/c/calliotx.com"
  },
  "status": null,
  "history_since": "2025-03-04T07:43:31.000Z",
  "baseline": {
    "snapshot_id": "7b0f241bec9c93814b82177982971c2b14c638e7d52f06373c474dfef735fed4",
    "observed_at": "2025-03-04T07:43:31.000Z",
    "headline": "Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes",
    "description": "We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.",
    "evidence": "https://web.archive.org/web/20250304074331/https://calliotx.com/",
    "evidence_kind": "internet_archive",
    "facts": {
      "version": 1,
      "pages": [
        {
          "page": "home",
          "customers": [],
          "investors": [],
          "prices": [],
          "compliance": [
            "FDA APPROVED",
            "FDA-APPROVED"
          ],
          "funding": [
            "AskBio and was part of the team that raised a USD 120Mn series B extension."
          ]
        }
      ]
    },
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T14:30:32.007Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2026-03-25T07:31:43.000Z",
      "variants": [
        {
          "headline": "Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes",
          "subhead": "We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.",
          "observed_at": "2025-03-04T07:43:31.000Z",
          "evidence": "https://web.archive.org/web/20250304074331/https://calliotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes",
          "subhead": "We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.",
          "observed_at": "2025-11-30T07:48:38.000Z",
          "evidence": "https://web.archive.org/web/20251130074838/https://calliotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes",
          "subhead": "We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.",
          "observed_at": "2026-03-25T07:31:43.000Z",
          "evidence": "https://web.archive.org/web/20260325073143/https://calliotx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes",
      "subhead": "We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.",
      "from": "2025-03-04T07:43:31.000Z",
      "to": "2026-03-25T07:31:43.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20260325073143/https://calliotx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2025-03-04T07:43:31.000Z",
          "to": "2026-03-25T07:31:43.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-06T14:30:32.007Z",
      "variants": [
        {
          "headline": "Blocking Cancer’s Escape.",
          "subhead": "Callio Therapeutics is advancing dual-payload antibody-drug conjugates (ADCs) designed to block cancer’s escape routes and deliver durable responses for underserved patient populations.",
          "observed_at": "2026-10-03T14:54:29.000Z",
          "evidence": "https://web.archive.org/web/20261003145429/https://calliotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Blocking Cancer’s Escape.",
          "subhead": "Callio Therapeutics is advancing dual-payload antibody-drug conjugates (ADCs) designed to block cancer’s escape routes and deliver durable responses for underserved patient populations.",
          "observed_at": "2026-10-27T20:45:05.000Z",
          "evidence": "https://web.archive.org/web/20261027204505/https://calliotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Blocking Cancer’s Escape.",
          "subhead": "Callio Therapeutics is advancing dual-payload antibody-drug conjugates (ADCs) designed to block cancer’s escape routes and deliver durable responses for underserved patient populations.",
          "observed_at": "2026-11-06T14:30:32.007Z",
          "evidence": "https://calliotx.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Blocking Cancer’s Escape.",
      "subhead": "Callio Therapeutics is advancing dual-payload antibody-drug conjugates (ADCs) designed to block cancer’s escape routes and deliver durable responses for underserved patient populations.",
      "from": "2026-10-03T14:54:29.000Z",
      "to": "2026-11-06T14:30:32.007Z",
      "captures": 3,
      "evidence": "https://calliotx.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2026-10-03T14:54:29.000Z",
          "to": "2026-11-06T14:30:32.007Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-13105a98ecb015caf73b58ef262c4974b3fd03713dd916f68fbc4fa29c601cd8:51f87a012b598d6e397d802fa240843f3d4bf300ba20f24da99215f77ef4f0a1:headline:0211a62931c736c6",
      "before_evidence": "https://web.archive.org/web/20260325073143/https://calliotx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes” to “Blocking Cancer’s Escape.”.",
      "between": {
        "from": "2026-03-25T07:31:43.000Z",
        "to": "2026-10-03T14:54:29.000Z"
      },
      "evidence": "https://web.archive.org/web/20261003145429/https://calliotx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 2,
      "id": "page-ac1926ea297c2f7cd8739f1a85a0a0586af3a34917961a98672e724079cb7dbb:2316d727b18cf167e97b21126fbd16f46cefafde949c149128c840c0abb70f5d:hiring:20dd4c09cc4ab0aa",
      "before_evidence": "https://web.archive.org/web/20261027204505/https://calliotx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "hiring",
      "label": "Hiring",
      "summary": "Added a careers page.",
      "between": {
        "from": "2026-10-27T20:45:05.000Z",
        "to": "2026-11-06T14:30:32.007Z"
      },
      "evidence": "https://calliotx.com/",
      "evidence_kind": "live_capture",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-careers-page"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Callio Therapeutics” company record, https://startuphistory.org/c/calliotx.com"
}